Abstract 2510
Background
Hand-foot syndrome (HFS) related to new targeted therapies is a common cutaneous toxicity, with potentially serious impacts on the patient QoL. Previous reports indicate that the incidence of HFS was about 30% in apatinib monotherapy for NSCLC. HFS was also reported to be associated with immunotherapy. We conducted a phase II clinical trial on apatinib combined with anti-PD-1 antibody SHR-1210 for advanced NSCLC (No. CTR20170090). Whether the combined therapy leads to a dramatic increase in the incidence of HFS remains uncertain. There are a variety of scales to evaluate the patients’ QoL, but the specific scale for patients with HFS needs further verification.
Methods
Multiply questionnaires including the HFS-specific QoL questionnaire (HFS-14), Dermatology Life Quality Index (DLQI), Skindex-16 and short-form 12 health-related questionnaire (SF-12) were developed to measure the effect of HFS on daily activities. The HFS clinical grade was based on NCI-CTCAE, v3.0.
Results
The validation study included 26 patients, of 21 (80%) developed HFS of varying grades, with 8 (31%) of grade 1, 7 (27%) of grade 2 and 6 (23%) of grade 3. 52% of patients declared involving one limb, and the rest patients developed HFS in both the hands and feet. The mean time to occurring HFS was 30 ± 64 days. In patients with various grades of HFS, the mean HFS-14 and DLQI scores were significantly higher with higher HFS grades, whereas the Skindex-16 and SF-12 scores did not differ. Four kinds of scales analysis also showed significant differences according to the degree of limb involvement, where the scores were significantly higher in patients having both hands and feet severely involved than in those having severe involvement of either only the hands or feet. When in patients with grade 2 HFS, the HFS-14 score was significantly higher in patients involving both the hands and the feet than in patients having only the hands or the feet severely affected; while Skindex-16, DLQI and SF-12 scores have no difference between these two groups.
Conclusions
The incidence of HFS induced by the treatment of anti-PD-1 antibody SHR-1210 combined with apatinib is extremely high. HFS-14 may serve as a more sensitive and valuable tool for early measuring HFS-related QoL impairment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1868 - Evaluation and diagnostic potential of plasma biomarkers in bladder cancer
Presenter: Veronika Voronova
Session: Poster Display session 3
Resources:
Abstract
3655 - Liquid biopsy assays using combined circulating tumor cells and circulating tumor DNA in the same patients for the diagnosis of primary lung cancer
Presenter: Yongjoon Suh
Session: Poster Display session 3
Resources:
Abstract
3685 - Peripheral Cytotoxic T Cell Correlates with Tumor Mutational Burden and is Predictive for Progression Free Survival in Advanced Breast Cancer
Presenter: Xiao-ran Liu
Session: Poster Display session 3
Resources:
Abstract
1050 - Splenic Metabolic Activity as Biomarker in Cervical Cancer
Presenter: Emiel De Jaeghere
Session: Poster Display session 3
Resources:
Abstract
1413 - Identification of distinct subtypes revealing prognostic and therapeutic relevance in diffuse type gastric cancer
Presenter: Seon-Kyu Kim
Session: Poster Display session 3
Resources:
Abstract
2140 - Recurrence risk evaluation in stage IB/IIA gastric cancer with TP53 codon 72 polymorphisms
Presenter: Satoshi Nishizuka
Session: Poster Display session 3
Resources:
Abstract
1573 - Identification and validation of a prognostic 4 genes signature for hepatocellular carcinoma: integrated ceRNA network analysis
Presenter: Yongcong Yan
Session: Poster Display session 3
Resources:
Abstract
1196 - Plasma KIM-1 is associated with clinical outcomes after resection for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805)
Presenter: Wenxin Xu
Session: Poster Display session 3
Resources:
Abstract
2657 - Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting
Presenter: Katharina Nekolla
Session: Poster Display session 3
Resources:
Abstract
4900 - Molecular profiling and prognostic significance of TP53 mutations in Diffuse Large B Cell Lymphoma: identifying a high-risk subgroup
Presenter: Yuan-Kai Shi
Session: Poster Display session 3
Resources:
Abstract